ERAL1 and breast cancer: The endoxifen conjugate 16b demonstrates antiproliferative activity in ER positive MCF-7 breast cancer cells (IC50 = 5.7 nM) and ER binding affinity to ERα (IC50 = 52 nM) and ERβ (IC50 = 115 nM).